Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut

Edwards Lifesciences (NYSE:EW) released its Q2 FY24 result on July 24th, with a disappointing guidance cut for its transcatheter aortic valve replacement (TAVR) revenue growth. I gave a 'Strong Buy' rating in my previous coverage published in February 2024, pointing out their EVOQUE Growth Opportunities. While TAVR growth is slowing down, I remain positive about the long-term growth potential. The sell-off of the stock creates a good entry point for buying. I reiterate my 'Strong Buy' with a fair value of $ ...